Trial Profile
A Phase Ib, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody(Sevacizumab) Injection Plus Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Sevacizumab (Primary) ; Paclitaxel; Topotecan
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Jiangsu Simcere Pharmaceutical
- 11 Dec 2018 New trial record